{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:09:28Z","timestamp":1790986168173,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian patients is uncertain. In this study, we conducted a systematic review and meta\u2010analysis to compare the CV safety profiles of febuxostat with allopurinol in Asian patients with hyperuricemia. A total of 13 studies were included. On the basis of the pooled results of cohort studies, febuxostat users were at a significantly higher risk for acute coronary syndrome (ACS; hazard ratio [HR]: 1.06, 95% confidence interval [CI]: 1.03\u20131.09,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01), atrial fibrillation (HR: 1.19, 95% CI: 1.05\u20131.35,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) than allopurinol users, whereas no significant difference between febuxostat and allopurinol existed for urgent coronary revascularization (HR: 1.07, 95% CI: 0.98\u20131.16,\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.13), and stroke (HR: 0.96, 95% CI: 0.91\u20131.01,\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.13). Nevertheless, that difference in results of acute decompensated heart failure (ADHF; HR: 0.73, 95% CI: 0.35\u20131.53,\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.40) and all\u2010cause death (HR\u2009\n                    <jats:italic>=<\/jats:italic>\n                    \u20090.86, 95% CI: 0.49\u20131.51,\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.60) was not significant based on randomized controlled trials. In the Chinese subgroup, febuxostat could increase the risk of ADHF (HR: 1.22, 95% CI: 1.01\u20131.48,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), CV death (HR: 1.25, 95% CI: 1.03\u20131.50,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), and all\u2010cause mortality (HR: 1.07, 95% CI: 1.01\u20131.14,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) compared to allopurinol. In conclusion, the use of febuxostat, compared with allopurinol among Asian patients, was associated with a significantly increased risk of adverse CV events.\n                  <\/jats:p>","DOI":"10.1111\/cts.13757","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T02:42:41Z","timestamp":1710556961000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A\u00a0systematic review and\n                    <scp>meta\u2010analysis<\/scp>"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-6383","authenticated-orcid":false,"given":"Jian\u2010hao","family":"Deng","sequence":"first","affiliation":[{"name":"Pharmacy Department Longyan Second Hospital  Longyan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng\u2010hui","family":"Lai","sequence":"additional","affiliation":[{"name":"Pharmacy Department Longyan Second Hospital  Longyan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010shan","family":"Xie","sequence":"additional","affiliation":[{"name":"Pharmacy Department Longyan Second Hospital  Longyan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu\u2010sheng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Pharmacy Department Longyan Second Hospital  Longyan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De\u2010sheng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Neurology Department Longyan Second Hospital  Longyan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0178-7007","authenticated-orcid":false,"given":"Jia\u2010xing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pharmacy Department Guizhou Provincial People's Hospital  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105286"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003025"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2022-0031"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0441-1"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000861"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1699-0"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00569-9"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"issue":"2017","key":"e_1_2_12_10_1","first-page":"29","article-title":"Updated EULAR evidence\u2010based recommendations for the management of gout","volume":"76","author":"Richette P","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114890"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895"},{"key":"e_1_2_12_13_1","unstructured":"USFDA.FDA Drug Safety Communication: FDA to evaluate increased risk of heart\u2010related death and death from all causes with the gout medicine febuxostat (Uloric).https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010fda\u2010evaluate\u2010increased\u2010risk\u2010heart\u2010related\u2010death\u2010and\u2010death\u2010all\u2010causes."},{"key":"e_1_2_12_14_1","unstructured":"USFDA.FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat).https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010adds\u2010boxed\u2010warning\u2010increased\u2010risk\u2010death\u2010gout\u2010medicine\u2010uloric\u2010febuxostat"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0"},{"key":"e_1_2_12_16_1","volume-title":"Medical Genetics Summaries","author":"Dean L","year":"2012"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_12_18_1","unstructured":"WellsGA SheaB O'connellD.The Newcastle\u2010Ottawa Scale (NOS)for assessing the quality of nonrandomised studies in meta\u2010analyses.2021."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz119"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211062770"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.11.076"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcme.2015.07.001"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1377"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez189"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.03.001"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez576"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.891606"},{"key":"e_1_2_12_28_1","first-page":"59","article-title":"Atrial fibrillation risk and urate\u2010lowering therapy in patients with gout: a cohort study using a clinical database","volume":"11","author":"Liu CH","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152080"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05222-0"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13439"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000065637.10517.A0"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000069700.62727.C5"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800885"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000066420.36123.35"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.12.004"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000573"},{"key":"e_1_2_12_40_1","first-page":"10","article-title":"Allopurinol protection of hepatic nuclear function during hemorrhagic shock","volume":"25","author":"Lazarus HM","year":"1974","journal-title":"Surg Forum"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)91112-0"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000313"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23643"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2019.06.016"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:32:15Z","timestamp":1744857135000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/cts.13757"],"URL":"https:\/\/doi.org\/10.1111\/cts.13757","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13757"}}